Počet záznamů: 1
Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin +/- prednisone addition to lenalidomide in refractory or relapsed patients)
- 1.
SYSNO ASEP 0506807 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin +/- prednisone addition to lenalidomide in refractory or relapsed patients) Tvůrce(i) Jonasova, A. (CZ)
Neuwirtová, R. (CZ)
Polackova, H. (CZ)
Šišková, M. (CZ)
Stopka, T. (CZ)
Cmunt, E. (CZ)
Belickova, M. (CZ)
Moudrá, Alena (UMG-J)
Minařík, L. (CZ)
Fuchs, O. (CZ)
Michalová, K. (CZ)
Zemanová, Z. (CZ)Celkový počet autorů 12 Zdroj.dok. Leukemia Research. - : Elsevier - ISSN 0145-2126
Roč. 69, June (2018), s. 12-17Poč.str. 6 s. Forma vydání Online - E Jazyk dok. eng - angličtina Země vyd. GB - Velká Británie Klíč. slova Myelodysplastic syndromes ; Lenalidomide ; Del(5q) aberration ; Erythropoietin ; Prednisone Vědní obor RIV EB - Genetika a molekulární biologie Obor OECD Cell biology Způsob publikování Omezený přístup Institucionální podpora UMG-J - RVO:68378050 UT WOS 000436483100003 DOI 10.1016/j.leukres.2018.03.015 Anotace Lenalidomide therapy represents meaningful progress in the treatment of anemic patients with myelodysplastic syndromes with del(5q). We present our initial lenalidomide experience and the positive effect of combining erythropoietin and steroids with lenalidomide in refractory and relapsed patients. We treated by lenalidomide 55 (42 female, 13 male, median age 69) chronically transfused lower risk MDS patients with del(5q) (45) and non-del( 5q) (10). Response, meaning transfusion independence (TI) lasting >= eight weeks, was achieved in 38 (90%) of analyzed patients with del(5q), of whom three achieved TI only by adding erythropoietin +/- prednisone. Another five patients responded well to this combination when their anemia relapsed later during the treatment. In the non-del(5q) group only one patient with RARS-T reached TI. Cytogenetic response was reached in 64% (32% complete, 32% partial response). The TP53 mutation was detected in 7 (18%) patients, four patients progressed to higher grade MDS or acute myeloid leukemia (AML). All seven RAEB-1 patients cleared bone marrow blasts during lenalidomide treatment and reached complete remission (CR), however, three later progressed to higher grade MDS or AML. Lenalidomide represents effective treatment for del(5q) group and combination with prednisone and erythropoietin may be used for non-responders or therapy failures. Pracoviště Ústav molekulární genetiky Kontakt Nikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217 Rok sběru 2020 Elektronická adresa https://www.sciencedirect.com/science/article/abs/pii/S0145212618300778?via%3Dihub
Počet záznamů: 1